MDGL Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025

11 days ago - By: Benzinga

Beyond The Numbers: 10 Analysts Discuss Madrigal Pharmaceuticals Stock

19 days ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Benzinga - Mentions: EA INSM MNTA NFLX ...

6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner

a month ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Yahoo Finance

Leerink Partners Maintains a Buy on Madrigal Pharmaceuticals (MDGL), Here’s Why

2 months ago - By: Investor's Business Daily - Mentions: NVO LLY

Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure

2 months ago - By: Yahoo Finance

Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)?

2 months ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Zacks Investment Research - Mentions: NVO RIGL AVDL

Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU

2 months ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

2 months ago - By: Investor's Business Daily - Mentions: NVO

Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal Pharma

3 months ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

3 months ago - By: The Motley Fool

Madrigal (MDGL) Q2 Revenue Soars 1,313%

3 months ago - By: Zacks Investment Research - Mentions: PROF

Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates

3 months ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates

3 months ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

3 months ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025

3 months ago - By: Yahoo Finance - Mentions: OWL GS

Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion

3 months ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH

3 months ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Madrigal Pharmaceuticals, Inc.

MADRIGAL PHARMACEUTICALS INC (MDGL) Stock News

MDGL Latest News, Press Relases and Analysis

Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025

Beyond The Numbers: 10 Analysts Discuss Madrigal Pharmaceuticals Stock

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Leerink Partners Maintains a Buy on Madrigal Pharmaceuticals (MDGL), Here’s Why

Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure

Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)?

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal Pharma

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Madrigal (MDGL) Q2 Revenue Soars 1,313%

Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates

Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025

Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion

Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)